Share This

Related Topics News -

     
 Title only   |   Print    Next page > 
     
《業績》科笛-B全年虧損收窄至4.34億元人民幣

2025-03-24T  
科笛治療頦下脂肪堆積藥物臨床試驗展現顯著且穩健療效優勢

2024-12-31T  
科笛新藥CU-20401臨床展現出顯著且穩健療效優勢

2024-11-29T  
科笛-B公布兩產品內地III期臨床試驗結果

2024-11-28T  
科笛獲首席執行官再增持5,200股

2024-11-18T  
科笛治療尋常痤瘡藥物獲內地上市批准

2024-11-12T  
科笛獲首席執行官上周五增持5,000股

2024-11-11T  
科笛-B首九個月商業化產品收入近1.5億人幣 按年升近1.3倍

2024-10-31T  
科笛重組突變膠原酶新藥II期臨床完成數據庫鎖定

2024-10-31T  
科笛獲首席執行官兩日增持2萬股

2024-10-17T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.